Cytosorbents (CTSO) vs NeuroOne Medical Technologies (NMTC)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Cytosorbents (CTSO) has outperformed NeuroOne Medical Technologies (NMTC) over the past year, losing 80.9% versus a loss of 82.7%. Over five years, NMTC leads with a -94.0% price change compared with -96.8% for CTSO. Cytosorbents is the larger company by market cap ($11.8 million vs $9.8 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CTSO | NMTC |
|---|---|---|
| Share price | $3.73 | $1.08 |
| Market cap | $11.75M | $9.83M |
| 1-day change | -3.62% | -2.70% |
| YTD return | -70.81% | -76.25% |
| 1-year return | -80.87% | -82.69% |
| 5-year return | -96.82% | -94.00% |
| EPS (TTM) | $-5.80 | $-0.99 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $19.72 | $6.42 |
| 52-week low | $3.66 | $0.962 |
| Distance from 52-week high | -81.09% | -83.18% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +1173.46% | +573.15% |
| Average volume | 12.45K | 339.60K |
| Shares outstanding | 3.15M | 9.11M |
| Employees | 129 | 18 |
| Sector | Healthcare | Healthcare |
| Industry | Medical Devices | Medical Devices |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Cytosorbents
CTSO stock →Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform in the United States, Germany, and internationally. Its flagship product, CytoSorb, is an extracorporeal blood purification cartridge to reduce cytokine storms in common critical illnesses, bilirubin in liver failure, myoglobin in trauma and critical illnesses, and inflammatory mediators and blood thinners in cardiac surgery applications, as well as to remove antithrombotic drugs and inflammatory mediators in cardiothoracic surgery applications.
Healthcare · Medical Devices · 129 employees
About NeuroOne Medical Technologies
NMTC stock →NeuroOne Medical Technologies Corporation, a medical technology company, provides solutions for continuous electroencephalogram (cEEG) and stereoelectrocencephalography (sEEG) recording in the United States. The company also provides solutions for spinal cord stimulation, brain stimulation, drug delivery and ablation solutions for patients suffering from epilepsy, trigeminal neuralgia, Parkinson's disease, dystonia, essential tremors, and chronic pain due to failed back surgeries and other pain-related neurological disorders.
Healthcare · Medical Devices · 18 employees
CTSO vs NMTC FAQ
Which is bigger, Cytosorbents or NeuroOne Medical Technologies?
Cytosorbents (CTSO) is larger, with a market capitalization of $11.75M compared with $9.83M for NeuroOne Medical Technologies (NMTC).
Which stock has performed better over the past year, CTSO or NMTC?
CTSO returned -80.87% over the past 12 months, compared with -82.69% for NMTC (price return, excluding dividends). Past performance does not predict future results.
Are Cytosorbents and NeuroOne Medical Technologies in the same industry?
Yes. Both are classified in the Medical Devices industry within the Healthcare sector.